PGNY
Progyny, Inc.
$31.98
+1.33 (+4.34%)
At close · Jul 13
Market Cap
$2.51B
Shares
78,332,370
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.29B
+10.4%
FY2025
Net Income
$58.52M
+7.7%
FY2025
Gross Margin
23.63%
+1.9pp
FY2025
Operating Margin
6.62%
+0.8pp
FY2025
Diluted EPS
$0.65
+14%
FY2025
Operating Cash Flow
$210.19M
+17.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.37B – $1.41B | $1.29B | $1.29B | $1.17B | $1.09B | $786.91M | $500.62M | $344.86M | $229.68M | $105.4M | $48.58M | |
| — | $3.11M | — | — | $3.3M | $814K | $461K | $121K | -$58K | -$497K | -$740K | |
| — | $981.37M | $984.18M | $913.86M | $849.8M | $619.59M | $388.49M | $274.8M | $184.18M | $85.97M | $41.18M | |
| — | $311.76M | $304.48M | $253.36M | $238.8M | $167.33M | $112.14M | $70.06M | $45.51M | $19.43M | $7.4M | |
| — | — | 23.63% | 21.71% | 21.94% | 21.26% | 22.4% | 20.32% | 19.81% | 18.44% | 15.23% | |
| — | — | $9.5M | — | — | — | — | — | — | — | — | |
| — | $71.21M | $72.11M | $63.95M | $59.49M | $45.66M | $20.18M | $15.01M | $11.9M | $7.29M | $4.26M | |
| — | $144.06M | $147.09M | $121.96M | $117.13M | $98.33M | $59.62M | $46.71M | $23.93M | $15.6M | $14.15M | |
| — | — | $800K | $100K | $100K | $500K | $600K | $1.2M | $1.5M | $1.5M | $1.5M | |
| — | — | $4.95M | $3.18M | $2.28M | $1.6M | $1.3M | $1.91M | $2.13M | $1.88M | $1.56M | |
| — | $215.27M | $219.21M | $185.91M | $176.62M | $143.98M | $79.8M | $61.71M | $35.83M | $22.89M | $18.41M | |
| — | $96.49M | $85.28M | $67.46M | $62.18M | $23.34M | $32.34M | $8.35M | $9.68M | -$3.45M | -$11.01M | |
| — | — | 6.62% | 5.78% | 5.71% | 2.97% | 6.46% | 2.42% | 4.21% | -3.28% | -22.65% | |
| — | — | $90.23M | $70.63M | $64.47M | $24.94M | $33.64M | $10.25M | $11.81M | -$1.57M | -$9.45M | |
| — | $9.29M | $10.16M | $15.75M | $8.51M | $1.1M | $95K | $331K | -$18.23M | -$3.44M | -$1.45M | |
| — | $105.78M | $95.43M | $83.2M | $70.69M | $24.44M | $32.44M | $8.68M | -$8.56M | -$6.89M | -$12.46M | |
| — | $38.09M | $36.91M | $28.87M | $8.65M | -$5.92M | -$33.33M | -$37.78M | $12K | -$1.78M | -$3000 | |
| — | $67.69M | $58.52M | $54.34M | $62.04M | $30.36M | $65.77M | $46.46M | -$8.57M | $661K | -$12.45M | |
| — | — | 4.54% | 4.66% | 5.7% | 3.86% | 13.14% | 13.47% | -3.73% | 0.63% | -25.63% | |
| — | $67.69M | $58.52M | $54.34M | $62.04M | $30.36M | $65.77M | $46.46M | -$8.57M | -$5.54M | -$13.47M | |
| — | $67.86M | $58.98M | $51.56M | $64.36M | $30.95M | $65.68M | $46.46M | -$8.57M | $661K | -$12.45M | |
| USD/shares | — | — | $0.68 | $0.59 | $0.65 | $0.33 | $0.74 | $0.54 | -$0.41 | $0.04 | -$2.37 |
| USD/shares | — | — | $0.65 | $0.57 | $0.62 | $0.30 | $0.66 | $0.47 | -$0.41 | $0.04 | -$2.37 |
| shares | — | — | 85.65M | 91.48M | 95.02M | 92.2M | 89.11M | 85.72M | 20.74M | 5.54M | 5.68M |
| shares | — | — | 89.86M | 95.45M | 100.67M | 99.96M | 100.36M | 99.06M | 20.74M | 5.54M | 5.68M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2025: $383.33M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Healthcare Plans median 0.57×
EV/EBIT
—
Healthcare Plans median 18.55×
P/E (TTM)
41.53×
Healthcare Plans median 41.53×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Reportable Segment | $1,288,661,000 | $1,167,221,000 | $1,088,598,000 | $786,913,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Fertility Benefit Services | $830,929,000 | $729,551,000 | $676,295,000 | $510,145,000 | $355,616,000 | $253,556,000 | $189,618,000 |
| Pharmacy Benefit Services | $457,732,000 | $437,670,000 | $412,303,000 | $276,768,000 | $145,005,000 | $91,302,000 | $40,065,000 |
Key facts
CIK
1551306
CUSIP
74340E103
13F (30d)
12 filings
12 filers
Visit website
Investor relations